Regulatory Insights

  1. Building Integrated Clinical Strategies For Complex Modalities 5/12/2026

    Explore how integrated strategies, digital tools, and patient-centric trial models are helping advance complex cell and gene therapy development.

  2. How To Best Navigate The Global Clinical Trial Registry Ecosystem 5/12/2026

    This presentation is your GPS, guiding you on a path that includes harmonization initiatives intended to improve transparency and data consistency across registries.

  3. FDA Nudges Sponsors To Disclose Clinical Trial Results 5/12/2026

    In March, the US FDA sent thousands of reminders to submit clinical trial results to ClinicalTrials.gov or complete the federal-mandated National Library of Medicine quality control review process.

  4. The State Of Materiovigilance: Capability Gaps, Technology Momentum, And Outsourcing Readiness 5/12/2026

    Explore how pharma and biotech companies are using AI, outsourcing, and new technologies to strengthen materiovigilance for complex drug-device products.

  5. Pharmacy Considerations For Early Phase Trials 5/8/2026

    This presentation explores practical pharmacy considerations in early-phase clinical trials, offering real-world insights from experienced clinical research pharmacists.

  6. Definitive QT Evaluation - Clinical And Operational Considerations 5/8/2026

    QT strategy decisions affect timelines, cost, and regulatory outcomes. This presentation examines when early QT data can support a waiver, how guidance updates influence study design, and more.

  7. How Remote Monitoring Is Transforming Compliance 5/8/2026

    Discover how remote monitoring is transforming pharmacy compliance. Shift from manual, onsite burdens to digital workflows that ensure real-time accuracy and continuous audit readiness.

  8. What The Joint FDA And EMA's AI Principles Can Mean For Clinical Trial Technology 5/6/2026

    New FDA/EMA principles align global expectations for AI in drug trials, emphasizing transparency, human-centric design, and risk-based governance to ensure data integrity and patient safety.

  9. A Blueprint For Modern Obesity Research 5/6/2026

    The landscape of obesity and GLP-1 research has reached a saturation point. To successfully scale to the 5,000-patient registries now required for long-term evidence, a shift in operational architecture is essential.

  10. Real-Time Data... Are We Fixing The Right Bottleneck (Or Any For That Matter)? 5/6/2026

    Real-time data streaming to regulators is a bold step, but true clinical acceleration requires solving site-level bottlenecks and data silos to reduce the administrative burden on research.